2019 Future Healthcare 100 Forum Opens, Seeking New Growth for Life

On December 20, 2019, hosted by VCBeat and Eggshell Research Institute, with KPMG China, Legend Capital, Baidu Ventures, For Future Capital, Puhua Capital, Tsinghua Nomura China Research Center, Long Hill Capital, Legend Star, Vision Capital, the Internet Hospital Branch of the Chinese Society of Research Hospitals, Aimeda, Zero2ipo Capital, andResearch ValueThe “2019 Top 100 Future Healthcare Companies” Forum, co-hosted by [Organizers], grandly opened at the Jiuhua Villa in Beijing.

As a dedicated observer and recorder of the innovative healthcare industry, VCBeat officially launched the Future Healthcare 100 Forum in 2015. Now in its fifth year, the forum has gradually grown into a premier branded event within the innovative healthcare sector.

The scale of this forum has reached a new high, attracting top medical and healthcare innovation enterprises, listed companies, financial institutions, and practitioners from medical institutions both domestically and internationally, with over 5,000 registrants.

The conference will host 15 forums over three days, covering the 11 key hotspots of 2019. These are: Future Healthcare Summit, Top 100 Enterprises Summit, Leadership Summit, Health and Medical Fund Partners Summit, China-Japan Health Industry Development Forum, Innovative Drugs Forum, Innovative Health Insurance Forum, Digital Pathology and Precision Diagnostics Forum, Health Management Forum, Medical Devices Forum, Internet Hospital Forum, Smart Hospital Construction Forum, Pharmaceutical Companies’ Digital Marketing Forum, Biotechnology Forum, and Medical Artificial Intelligence Forum.

The theme of this forum is “New Growth in Life.” The innovative healthcare industry began to rise in 2016, with companies emerging rapidly like bamboo shoots after rain as they sought “upward momentum.” In 2017, the sector entered an era of “species explosion.” By 2018, as the industry gradually matured, it began to reexamine ecological synergy and explore “viable paths for new frontiers.”

In 2019, the innovative healthcare industry urgently needed to identify “new sources of vitality.” Accordingly, this summit focused on multiple factors—including the policy landscape, technological environment, and market demand—to comprehensively analyze future trends in the healthcare sector and drive transformation within the innovative health and medical industry.

The summit attracted numerous industry leaders, who provided in-depth analysis and discussion on future trends in innovative healthcare. Particularly notable was the “Top 100 Future Healthcare Summit,” which spanned the entire day of the 20th. Distinguished speakers included Liu Zhefeng, Deputy Director of the Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration; Cheng Yi, Senior Vice President of WeDoctor Group; Li Tiantian, Founder and Chairman of DXY; Xu Bo, Operating Partner at Weimai and Head of the Platform/Internet Hospital Center; Wang Hang, CEO of Haodf Online; Kong Fei, CEO of More Health; Dr. Shi Lei, Vice President of YITU Healthcare; and Guo Xiaohong, Co-founder and Vice President of SENYINT.

Highlights of Guest Speakers’ Views:

In the future, Hainan Boao Lecheng will achieve breakthrough progress in establishing advanced clinical medical centers with specialized technologies and bases for the research, development, and translation of cutting-edge medical technologies, thereby realizing the “triple synchronization” of medical technologies, equipment, and pharmaceuticals with international advanced standards. In the near future, the medical services and scientific research capabilities of Hainan Boao Lecheng will reach a leading position domestically and an advanced level internationally, fully forming industrial agglomeration and brand effects, and establishing itself as a world-class international medical tourism destination and a platform for medical technology innovation.

Future healthcare should be digital-driven; it should be people-centric, with greater emphasis on balance and sharing; and it should be health-centered. WeDoctor has pioneered and is currently implementing the Digital Health Community solution, which integrates city, county, township, and village levels, and connects medical care, pharmaceuticals, insurance, and elderly care. This initiative helps cities across China improve medical service efficiency and builds an efficient health maintenance system that focuses on the “full life cycle and entire health process” of the public, empowering individuals to understand and take control of their own health.

Strong medical foundations and beyond-expectation experiences define high-quality services. DXY’s consumer-facing brand, Dingxiang Doctor, leverages its robust medical expertise to become the most trusted brand in the Chinese internet’s broad health sector, continuously producing impactful content tailored to specific demographics and lifestyles. Meanwhile, Dingxiang Doctor’s online consultation service adheres to evidence-based medicine and adopts a user-centric approach, addressing pain points such as incomplete, non-comprehensive, and poor-quality online consultations, thereby delivering an experience that exceeds user expectations.

Based on the user's healthcare service journey, Weimai continuously establishes new service relationships—such as those between patients and hospitals, patients and physicians, and families and family doctors—to address users' healthcare consumption decision-making challenges. Meanwhile, Weimai supports public hospitals in upgrading their basic services for greater public convenience, while continually enriching physician/departmental services and social private-sector offerings. By innovating multi-tiered service supply for public hospitals and delivering innovative service content to users—including enhanced basic medical care experiences, disease-specific/specialty/surgical management services, and family/corporate membership programs—Weimai serves as the foundational service infrastructure for hospitals.

Following the clarification of reform policies, while healthcare operates as a market-driven activity, its public welfare nature remains the core principle. In response to the industry’s prevailing tendency to prioritize clinical treatment over patient services, Haodf Online has made enhancing service quality and improving patient satisfaction its key focus this year. In 2019, Haodf Online received nearly 1.4 million user feedback entries, with expressions of gratitude and commendations for doctors accounting for 33%, while the volume of complaints dropped significantly. Haodf’s efforts to optimize service quality are aimed at achieving long-term sustainability.

In the realm of health management, Miao Health is committed to “transforming health through technology” by exploring AI-driven intelligent interventions. The company has built two core capabilities (the H Platform and the M Platform) to serve two major scenarios (insurance and enterprise), providing health management services to two types of clients. This is achieved by delivering lightweight online management to users via the Miao App, while offering intensive offline management through its Canadian Health Management Center.

Medical AI is gradually maturing on both the technological and solution fronts, becoming a new driving force on the healthcare supply side. In a year marked by rapid and steady development in the AI healthcare industry, leading enterprises represented by Yitu Medical have spearheaded three major new trends:1. From “Single” to “Comprehensive”: Integrating multimodal data with AI technologies to move beyond the detection of single lesions, expanding coverage to multiple diseases and achieving full-body assisted diagnosis.2. Empowering Primary Care: Leveraging the “AI+” diagnostic and treatment model to enhance the homogenization of diagnostic quality at the primary care level, while using “AI+” to support tiered diagnosis and treatment systems, thereby balancing regional medical resources.3. Integration of Software and Hardware: Combining software and hardware at the underlying technology level to increase intelligence density, and integrating them at the application layer to achieve joint debugging and optimization, meeting diagnostic and treatment needs across diverse scenarios.

SENYINT has built and operates China's largest medical cloud platform, offering a comprehensive suite of solutions that include the Medical Consortium Cloud Platform, regional health information systems, internet hospitals, and digital hospital frameworks. With the industry's most complete product matrix, SENYINT fully supports the smart transformation of hospitals and drives innovation in medical services. Currently, the medical cloud platform constructed by SENYINT serves 80% of China's Grade A tertiary hospitals, covering more than 7,000 hospitals across 31 provinces.

The afternoon session on the 20th was equally compelling. Kang Shigong, Co-founder of Quanyu Medical; Li Yuhui, Founding Managing Partner and Chairman of Panlin Capital; Ma Dong, Partner and Vice President of Taimei Medical Technology; Li Jingjue, Senior Partner, Vice President, and CEO of Greater China at BioMind; Gao Chuan, Vice President of the United Imaging U+ Internet Healthcare Division; Zhou Sixiang, Head of Business Development for Asia-Pacific at Harbour BioMed; and Jiang Lu, General Manager of the Aggregated Business Department at Shuidi Inc., also shared their insights on innovative healthcare.

Highlights of Guest Speakers’ Views:

A closed-loop ecosystem for the entire radiotherapy industry under the "O+O" model is taking shape. By leveraging a comprehensive information management system, diversified value-added services, standardized precision radiotherapy centers, professional maintenance teams, high-quality consumable supplies, and advanced Quanyu Cancer Hospitals, Beijing Quanyu Medical Technology Co., Ltd. is building a super medical consortium through its Precision Cloud Radiotherapy platform, thereby facilitating the decentralization and sharing of high-quality medical resources.

Since its inception, Panlin Capital has adhered to the strategy of “selective targeting and concentrated investment.” Whether it involves technology, products, or the founding team, all must withstand market validation. Each successful validation of a project may serve as a trigger for Panlin Capital to increase its investment. A common approach employed by Panlin Capital in specific healthcare investments is to lead the initial funding round, participate in follow-on investments with anti-dilution provisions in the second round, and then make substantial additional investments once the project achieves significant milestones.

Digital operational management models will become a powerful tool for pharmaceutical companies to enhance their core competitiveness. Underpinned by digital technologies, enterprises can build self-evolving capabilities, streamline complex management and operations, and enable collaborative linkages across the pharmaceutical industry. Taimei Medical Technology is committed to building the digital infrastructure for the pharmaceutical industry—the TrialOS Pharmaceutical R&D Collaboration Platform—to achieve multi-party digital connectivity and define new operational standards for the sector. To date, TrialOS has provided digital services to over 600 leading pharmaceutical companies and CROs, as well as more than 1,600 medical institutions, supporting the execution of over 2,000 clinical research projects.

The role of AI in medical imaging is to empower, not replace, auxiliary diagnosis and treatment decisions. Specifically, BioMind’s CT/MR Imaging Auxiliary Diagnosis System provides multi-organ and multi-disease auxiliary diagnosis and risk assessment through its intelligent auxiliary diagnosis system, intelligent MDT (Multidisciplinary Team) integrated analysis, and intelligent emergency warning capabilities, thereby offering additional information and clinical decision support.

United Imaging Cloud Expands Its Business Model from B2B to B2C. Currently, United Imaging Cloud connects 1,500 devices and over 1,200 hospitals, aggregating more than 4 million imaging cases in the cloud.

China’s biopharmaceutical industry has made significant strides in biosimilars, yet there remains substantial room for improvement in innovative biologics. Meanwhile, the lack of fully human antibody platforms has become a widely recognized bottleneck in industry development. In the future, the use of fully human transgenic mice to develop fully human antibodies will lead the advancement of the antibody drug sector, while fully human single-domain antibodies will see broader applications in the development of bispecific antibodies.

Waterdrop Inc. provides pre-event protection through Waterdrop Insurance Mall and Waterdrop Mutual Aid, while offering post-event assistance via Waterdrop Crowdfunding and Waterdrop Charity. The company aims to build a comprehensive supplementary medical payment system and establish itself as China’s leading internet health protection platform. In the future, Waterdrop Inc. hopes to work together with partners in the healthcare sector to enable members to access better diagnosis and treatment at lower costs.

The Future Healthcare 100 List (abbreviated as VB100) is the first domestic ranking list targeting non-listed companies in the innovative medical and health sector, jointly launched by VCBeat and Eggshell Research Institute in 2015. It aims to select Chinese innovative enterprises that truly represent the future of healthcare, identify the core forces driving China's future medical and health industry, and promote the process of innovation and transformation in the medical and health sector.

The 2019 Future Healthcare Top 100 List has optimized and upgraded its structure and content based on the experience accumulated from previous years. The 2019 list comprises five main rankings and eighteen sub-rankings, covering four major sectors—medical services, innovative medical devices, digital health, and innovative pharmaceuticals—as well as dozens of niche fields, including third-party medical imaging centers, mental health, electronic medical records (EMR), surgical robots, and rehabilitation equipment.

Meanwhile, VCBeat Research Institute released the “2019 Future Healthcare 100 Growth Report: Data-Driven Insights into Growth Trajectories” at the summit, providing an analysis of the growth journeys and future development trends of selected representative companies included in the Future Healthcare 100 list.

For information on the five major main rankings and the growth report of representative enterprises, please refer to:“2019 Future Healthcare Top 100 List Released: Data Insights into Corporate Growth Trajectories”

The following are the sub-lists announced at this summit:

The summit will run until December 22, with more than a dozen themed forums poised to deliver insightful and in-depth interpretations on how practitioners in the innovative healthcare industry can “discover new growth drivers for life.”